Transcript Akshaya Bio Inc.

Chimigen® Platform Technology
Chimigen® Technology-Based
Molecular Vaccines
Novel Approach to an Established Concept
Dendritic Cell Receptor-Targeted Vaccines
Akshaya Bio Inc.
1
Chimigen® Recombinant Molecule
6xHis
6xHis
Antigen
Antigen
CHO
IRD
CHO
Peptide Linker
Portion of CH 1
S-S
Hinge Region
S-S
S S
CHO
CH2 S S CCH2
H2
Xenotypic
(Murine) Fc
CHO
TBD
SS
SS
C H3
CH3
Peptide
Strong Intellectual Property Position
11 Issued Patents, 36 Patent Applications Pending worldwide
Akshaya Bio Inc.
2
Chimigen® Platform Technology
• Characteristics of both Antigen (Ag) and Antibody (Ab)
• Xenotypic (foreign) Ab fragment makes whole molecule “foreign”
& thus more immunogenic
• Adaptable platform
– Adaptable to disease-specific multiple molecular antigenic
epitopes
– HBV, HCV, HIV, Biodefence Applications (Alphaviruses),
Pandemic Preparedness (H5N1, H1N1), Malaria, Cancer etc.
• Designed to generate broad immune responses
– Cellular (Class I) – critical to clear virus infected & cancer cells
– Humoral (Class II) – Antibodies
• Potential use for both Prophylactic & Therapeutic Vaccines
Akshaya Bio Inc.
3
Chimigen® Platform Technology
•
Effective at low doses (µg)
– Targets multiple cell types relevant to immune activation
– Targets multiple specific receptors on Antigen Presenting Cells
• Dendritic Cells (Fcγ, Lectin Receptors)
•
Minimal safety concerns
– Utilizes classical antigen presentation pathway
– No added adjuvant
•
Ease of production and scalability
– Utilizes insect cell-based production
– Established purification systems
– Potentially, increased antigenicity through production of the
chimeric molecule in Insect Cells
• Imparts non-mammalian glycosylation
– Binding and uptake through Fc and Lectin receptors
• Highly immunogenic
Akshaya Bio Inc.
4
Applications & Status of Programs
•
HBV Therapeutic Vaccine/ Prophylactic Vaccine
•
•
HCV Therapeutic & prophylactic Vaccine
•
•
Preclinical completed (Licensed to Nuron)
Preclinical Continuing (Nuron support)
HIV Prophylactic/Therapeutic Vaccine
•
Discovery (CHTD-NRC-IRAP)
•
Cancer Vaccine
•
Biodefense and Pandemic Applications
•
•
Alphavirus (WEEV) vaccine, Preclinical
Malaria
•
Late discovery stage (Gates Foundation)
•
Influenza H5 & H1
•
RNAi Therapeutics
Akshaya Bio Inc.
5
Akshaya Bio Inc.
Product Pipeline…..
Akshaya Bio Inc.
6
Chimigen® HBV Therapeutic/Prophylactic Vaccine
6xHis
6xHis
HBV
S1/S2/Core
HBV
S1/S2/Core
CHO
IRD
CHO
Peptide Linker
Portion of CH1
S-S
Hinge Region
S-S
SS
CHO
CH2
Xenotypic
Murine Fc
SS
CHO
CCH2
H2
TBD
SS
SS
CH3
CH3
Peptide
Contains T & B cell-relevant HBV antigens
Akshaya Bio Inc.
7
Chimigen® HCV Prophylactic/Therapeutic Vaccine
Chimigen® HCV E1-E2-NS5A Vaccine
6xHis
6xHis
HCV
E1-E2-NS5A
HCV
E1-E2-NS5A
IRD
CHO
CHO
Peptide Linker
Portion of CH1
S-S
Hinge Region
S-S
SS
CHO
CH2 S S CCH2
H2
Xenotypic Fc
CHO
TBD
SS
SS
CH3
CH3
Peptide
Contains two B cell and one T-cell relevant HCV antigens
Akshaya Bio Inc.
8
Chimigen® Malaria Vaccine
Multi-antigen Vaccine
6xHis
Malaria
antigens
Malaria
antigens
(CSP/AMA-1/LSA120 repeats/MSP-142)
(CSP/AMA-1/LSA120 repeats/MSP-142)
HBV Core
HBV Core
CHO
6xHis
IRD
CHO
Peptide Linker
Portion of CH1
Hinge Region
S-S
S-S
S S
Xenotypic
(Murine)Fc
CHO
CHO
CH2 S S CCH2
H2
TBD
S S
CH3
S S
CH3
Peptide
Targets the parasite at various stages of the infection
Akshaya Bio Inc.
9
Chimigen® HIV Vaccine
Multi-antigen Vaccine
6xHis
6xHis
HIV antigens
HIV antigens
Gag/env/tat/rev/vpr/vpu
Gag/env/tat/rev/vpr/vpu
CHO
IRD
CHO
Peptide Linker
Portion of CH1
Hinge Region
S-S
S-S
S S
Xenotypic
(Murine)Fc
CHO
CHO
CH2 S S CCH2
H2
TBD
S S
CH3
S S
CH3
Peptide
Targets the virus at various stages of the infection
Akshaya Bio Inc.
10
Chimigen® Muc1 Cancer Vaccine
Possible Universal Cancer Vaccine
MUC1
5xTandem
Repeat
MUC1
5xTandem
Repeat
CHO
IRD
CHO
Peptide Linker
Portion of CH1
S-S
Hinge Region
S-S
SS
CHO
CH2 S S CCH2
H2
Xenotypic
Murine Fc
CHO
TBD
SS
SS
CH3
CH3
Peptide
MUC1 is over-expressed in a large number of carcinomas
Akshaya Bio Inc.
11
Chimigen® WEEV Vaccine
6xHis
6xHis
WEEV
E1-E2
WEEV
E1-E2
CHO
IRD
CHO
Peptide Linker
Portion of CH1
S-S
Hinge Region
S-S
SS
CHO
CH2
SS
CHO
CCH2
H2
Xenotypic Fc
TBD
SS
SS
CH3
CH3
Peptide
Akshaya Bio Inc.
12
Chimigen® Influenza Vaccine
6xHis
6xHis
Influenza
H5(H1)-M2
IRD
Influenza
H5(H1)-M2)
CHO
CHO
Peptide Linker
Portion of CH1
S-S
Hinge Region
S-S
SS
CHO
CH2
Xenotypic
Murine Fc
SS
CHO
CCH2
H2
TBD
SS
SS
CH3
CH3
Peptide
Akshaya Bio Inc.
13
Chimigen® Vaccine Platform
Highlights
• Versatile, Adaptable Platform
• Dendritic Cell Receptor-Targeted Vaccines
• Generates broad immune responses
• Cellular (Class I) - critical to clear virus infected &
cancer cells
• Humoral (Class II) – Abs- Helps CTLs
• Proof of principle established with Chimigen® HBV
Therapeutic Vaccine
• Potential use for both Prophylactic & Therapeutic
Vaccines
• Strong Intellectual Property Position
Akshaya Bio Inc.
14